HK1103660A1 - Stabilised supersaturated solids of lipophilic drugs - Google Patents

Stabilised supersaturated solids of lipophilic drugs

Info

Publication number
HK1103660A1
HK1103660A1 HK07112356.6A HK07112356A HK1103660A1 HK 1103660 A1 HK1103660 A1 HK 1103660A1 HK 07112356 A HK07112356 A HK 07112356A HK 1103660 A1 HK1103660 A1 HK 1103660A1
Authority
HK
Hong Kong
Prior art keywords
lipophilic drugs
solids
stabilised
stabilised supersaturated
supersaturated solids
Prior art date
Application number
HK07112356.6A
Other languages
English (en)
Inventor
Adrian Funke
Torsten Wagner
Ralph Lipp
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1103660(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of HK1103660A1 publication Critical patent/HK1103660A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HK07112356.6A 2004-03-10 2007-11-12 Stabilised supersaturated solids of lipophilic drugs HK1103660A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10
PCT/IB2005/000748 WO2005087199A2 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Publications (1)

Publication Number Publication Date
HK1103660A1 true HK1103660A1 (en) 2007-12-28

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112356.6A HK1103660A1 (en) 2004-03-10 2007-11-12 Stabilised supersaturated solids of lipophilic drugs

Country Status (33)

Country Link
US (1) US8715735B2 (ja)
EP (2) EP2087883B1 (ja)
JP (1) JP5006185B2 (ja)
KR (1) KR101210695B1 (ja)
CN (1) CN1984644B (ja)
AR (1) AR048500A1 (ja)
AT (1) ATE442131T1 (ja)
AU (1) AU2005221403B8 (ja)
BR (1) BRPI0507342A (ja)
CA (1) CA2558582C (ja)
CR (1) CR8630A (ja)
DE (1) DE602005016551D1 (ja)
DK (1) DK1765290T3 (ja)
EA (1) EA012746B1 (ja)
EC (1) ECSP066902A (ja)
ES (2) ES2332229T3 (ja)
GT (1) GT200500045A (ja)
HK (1) HK1103660A1 (ja)
HR (1) HRP20090614T1 (ja)
IL (1) IL177894A0 (ja)
MY (1) MY142989A (ja)
NO (1) NO20064473L (ja)
NZ (1) NZ549793A (ja)
PA (1) PA8626101A1 (ja)
PE (1) PE20060016A1 (ja)
PL (1) PL1765290T3 (ja)
PT (1) PT1765290E (ja)
RS (1) RS51076B (ja)
SI (1) SI1765290T1 (ja)
SV (1) SV2005002044A (ja)
TW (1) TWI345986B (ja)
UY (1) UY28803A1 (ja)
WO (1) WO2005087199A2 (ja)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
EP1898880A2 (en) * 2005-06-16 2008-03-19 Warner Chilcott Company Inc. Gel compositions for topical administration
US10016442B2 (en) * 2005-06-16 2018-07-10 Allergan Pharmaceuticals International Limited Estrogen compositions for vaginal administration
US20090312439A1 (en) * 2006-05-10 2009-12-17 Ralph Hofmann Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
PL2487161T3 (pl) 2007-02-23 2017-03-31 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
US20100119601A1 (en) * 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
CN101945646A (zh) * 2008-02-13 2011-01-12 拜耳先灵医药股份有限公司 含雌二醇的药物递送系统
WO2009113522A1 (ja) * 2008-03-11 2009-09-17 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
SG190618A1 (en) 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
JP2012505253A (ja) * 2008-10-10 2012-03-01 テバ ウィメンズ ヘルス インコーポレイテッド 低用量酢酸シプロテロンを用いる、去勢された前立腺癌患者における血管運動症状の治療方法
CA2752805A1 (en) * 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016014454A1 (en) 2014-07-21 2016-01-28 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
PL3582627T3 (pl) * 2017-02-14 2022-01-17 Dsm Ip Assets B.V. Formulacje stabilne podczas przechowywania
EP3582626B1 (en) * 2017-02-14 2021-09-15 DSM IP Assets B.V. Water dispersible formulations
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) * 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
ES2062634T3 (es) 1990-08-30 1994-12-16 Senju Pharma Co Composicion con liberacion controlada del farmaco.
EP0492007B1 (en) * 1990-11-29 1995-02-08 F.H. FAULDING & CO. LIMITED Process for producing liquid loaded powders
DE4326240A1 (de) 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
IL148339A0 (en) 1999-08-31 2002-09-12 Schering Ag Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
SK288129B6 (sk) 2000-01-18 2013-10-02 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormonal substitution treatment
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
EA006777B1 (ru) * 2001-06-22 2006-04-28 Пфайзер Продактс Инк. Фармацевтические композиции адсорбатов аморфного лекарственного средства
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
AU2003263663A1 (en) 2002-09-05 2004-03-29 Pantarhei Bioscience B.V. Pharmaceutical application of 15- or 16- substituted testosterone analogues
EP1558265B1 (en) 2002-11-05 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Use of drospirenone for the treatment of hypertension
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
CA2516096A1 (en) 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
EA012570B1 (ru) 2004-03-10 2009-10-30 Шеринг Акциенгезельшафт Твердая или полутвердая композиция, содержащая молекулярно диспергированный дроспиренон, и способ ее получения

Also Published As

Publication number Publication date
DK1765290T3 (da) 2009-11-02
ECSP066902A (es) 2006-12-20
ES2390406T3 (es) 2012-11-12
UY28803A1 (es) 2005-10-31
WO2005087199A2 (en) 2005-09-22
BRPI0507342A (pt) 2007-07-03
DE602005016551D1 (de) 2009-10-22
MY142989A (en) 2011-02-14
PE20060016A1 (es) 2006-02-16
EP2087883A1 (en) 2009-08-12
NO20064473L (no) 2006-10-10
EP1765290B1 (en) 2009-09-09
NZ549793A (en) 2010-06-25
EA012746B1 (ru) 2009-12-30
JP2007528389A (ja) 2007-10-11
PL1765290T3 (pl) 2010-02-26
AU2005221403B2 (en) 2009-12-10
HRP20090614T1 (hr) 2009-12-31
JP5006185B2 (ja) 2012-08-22
US8715735B2 (en) 2014-05-06
CR8630A (es) 2007-06-06
PT1765290E (pt) 2009-11-23
ES2332229T3 (es) 2010-01-29
AU2005221403A1 (en) 2005-09-22
US20050207990A1 (en) 2005-09-22
KR101210695B1 (ko) 2012-12-11
KR20060132999A (ko) 2006-12-22
EA200601588A1 (ru) 2007-02-27
CN1984644A (zh) 2007-06-20
RS51076B (sr) 2010-10-31
SI1765290T1 (sl) 2010-01-29
AR048500A1 (es) 2006-05-03
WO2005087199A3 (en) 2009-01-15
EP1765290A2 (en) 2007-03-28
TWI345986B (en) 2011-08-01
PA8626101A1 (es) 2006-07-03
SV2005002044A (es) 2005-11-04
CA2558582C (en) 2013-07-16
CN1984644B (zh) 2010-12-08
CA2558582A1 (en) 2005-09-22
WO2005087199A8 (en) 2007-03-29
GT200500045A (es) 2005-10-31
ATE442131T1 (de) 2009-09-15
AU2005221403B8 (en) 2010-01-07
TW200600116A (en) 2006-01-01
EP2087883B1 (en) 2012-07-25
IL177894A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
TWI345986B (en) Stabilised supersaturated solids of lipophilic drugs
EP1646368A4 (en) DOSIFIED FORMS CONTAINING TWO SEPARATELY IMPROVED MEDICINES
PL373914A1 (en) Immediate release dosage forms containing solid drug dispersions
IL206888A0 (en) Compound capable of binding s1p receptor and pharmaceutical use thereof
HK1106275A1 (en) Preparation of nanoparticle materials
IL187387A0 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
IL173866A0 (en) Sustained release dosage forms of ziprasidone
EP1531844A4 (en) NOVEL PROLONGED RELEASE PHARMACEUTICAL COMPOUNDS FOR PREVENTING THE ABUSE CONSUMPTION OF CONTROLLED SUBSTANCES
EP1951211A4 (en) TRANSDERMAL PREPARATIONS CONTAINING NON-STEROID HYDROPHOBIC ANTI-INFLAMMATORY DRUGS
IL176932A0 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
EP1796676A4 (en) TRANSDERMALE ADMINISTRATION OF PHYCOTOXINES
GB0416728D0 (en) Medicinal use of receptor ligands
EP1778252A4 (en) NON-CARDIOTOXIC PHARMACEUTICAL COMPOUNDS
EP1651211A4 (en) COMBINATION OF MEDICAMENTS FOR THE TREATMENT OF NEOPLASMS
IL190323A0 (en) Kit for the parenteral administration of drugs
IL176061A0 (en) Nitrooxyderivatives of antihypertensive drugs
GB0327742D0 (en) Novel uses of known drugs
GB0328040D0 (en) Pharmaceutical uses of bisphosphonates
GB0424742D0 (en) Pharmaceutical compounds
GB0327389D0 (en) Stabilised pharmaceutical compositions
GB0414196D0 (en) Medicinal use of receptor ligands
GB0424015D0 (en) Medicinal use of receptor ligands
GB0412198D0 (en) Medicinal use of receptor ligands
GB0414194D0 (en) Medicinal use of receptor ligands
GB0414195D0 (en) Medicinal use of receptor ligands

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE PRIORITY APPLICATION NO. FROM 14075714.8 TO 04075714.8

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150310